Kornimate/medical-research-clean huggingface dataset:
tumor characteristics and survival rate of her2-low breast cancer patients

Conditions: HER2 Low Breast Carcinoma

Summary: in this large-scale cross-sectional study, we evaluated disease-free survival (dfs), overall survival (os), and clinicopathological characteristics of bc patients from 1991 to 2022, retrospectively. we recruited patients referred to the cancer research center in tehran, iran, and their her2 status, which is classified as her2-low, her2-positive, or her2-negative, was obtained from prospectively maintained registries. we aimed to dive more deeply into the clinicopathological characteristics and survival features of her2-low breast cancer patients and campared it with her2-negative and her2-positive groups. question 1: is her2-low breast cancer (bc) a new subtype in the standard classification of bcs? question 2: how is the dfs and os rate of her2-low breast cancer patients in comparison with her2-negative and her2-positive groups?


Eligibility criteria:
inclusion criteria: all breast cancer patients with human epidermal growth factor receptor 2 (her2) status in the database of the cancer research center (crc),from april 1991 to march 2022 exclusion criteria: the male gender patients with indeterminate or missing her2 status, or patients with missing dfs and os information

Keywords: breast cancer, erbb-2, her2-low, disease-free survival, survival rate
evaluation of long-term continuity of exercises in low back pain individuals

Conditions: Chronic Low-back Pain

Summary: identification of the long term effects of exercises in individuals with low back pain.

individuals with low back pain who will participate in the study will be divided into two groups. in the stabilization exercise group will be instructed to perform spinal stabilization exercises and in the yoga group will be instructed to perform yoga program consisting of breathing, relaxation and flexibility exercises. the intensity of the pain will be evaluated through visual analog scale, functional status and quality of life will be evaluated through oswestry disability index(odi), nottingham health profile (nhp), respectively. the exercise adherence will evaluated exercise adherence rating scale (ears). the time-distance characteristics of the gait will be evaluated by the optogait photoelectric cell (optogait, microgate, italy, 2010) and the treadmill system. assessments will be repeated before, after the treatment, 6 and 12 month follow-up. also,the number of back pain attacks of the individuals will be questioned and recorded.

Eligibility criteria:
inclusion criteria: * must be low back pain at least 3 months * must be visual analog scale rating 3 or more exclusion criteria: * history of any lumbar spine surgery * severe/progressive scoliosis * spinal stenosis * spondylolisthesis * cancer * diabetes * metabolic syndrome * history of exercise programs or yoga at least 12 weeks before the onset of study

Keywords: exercise pain yoga function
effectiveness of a psychological intervention in patients undergoing total knee arthroplasty

Conditions: Knee Arthroplasty, Total

Summary: the purpose of this study is to evaluate the effectiveness of a combined pain neuroscience education (pne) and hypnosis (hyp) psychological intervention aiming at the control and prevention of pain and promotion of post-surgical recovery in patients undergoing total knee arthroplasty

this is a prospective randomized controlled trial (rct), comparing an experimental group (eg), submitted to a pne/hyp based psychological intervention, and a control group (cg), submitted to usual treatment and care. after recruitment and evaluation of inclusion/exclusion criteria, patients entering the study will sign the informed consent. baseline evaluation is performed at 1 month pre-surgery and, afterwards, patients are randomly assigned to eg (pne+hyp plus usual care) or cg (usual care only). the eg will be submitted to 3 pre-surgical and 1 (or 2) post-surgical reinforcement sessions. at 1 month post-surgery, the intervention group will be subdivided and participants will be randomly assigned to receive a reinforcement session or no intervention at this point. the psychological intervention sessions are based on the educative principles of pain neuroscience education and on hypnosis strategies for the promotion of pain control, positive coping strategies and psychological variables. patients will be evaluated on 6 moments: t0 - baseline, 1 month pre surgery; t1 - post intervention/24h before surgery; t2 - 72h post-surgery; t3 - 1 month post surgery; t4 - 6 months post surgery; t5 - 12 months post intervention. patients will fill in self report measures and perform physiological evaluation to analyse relevant bio-markers (salivary cortisol and α-amylase) that are related to stress levels and sns functioning and translate the impact of psychological interventions on physiological parameters.

Eligibility criteria:
inclusion criteria: * planned unilateral total knee arthroplasty due to gonarthrosis * giving consent to participate exclusion criteria: * inability to write and read * cognitive deficit (assessed by mmse) * revision tka * bilateral tka * tka for reasons other than gonarthrosis (fracture, malignancy or infection) * psychiatric or neurological deficit (e.g. schizophrenia or alzheimers') * diagnosis of rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, anquilosant spondylitis or other severe disease * contralateral hip or knee arthroplasty in the previous 6 months * planned contralateral hip or knee arthroplasty in the next 6 months

Keywords: knee arthroplasty hypnosis pain neuroscience education pain catastrophizing optimism distress hope self-efficacy
cancer fatigue education program

Conditions: Patient With Histologically Confirmed Malignancy

Summary: the purpose of the present project is to develop, implement and evaluate a pilot regional patient education program on the management of one of the main side effects of chemotherapy in cancer patients, that is fatigue. a carer (doctor or nurse) trained in educational techniques will be responsible for the patient. the carer will first identify modes of behavior and competences that the patient must acquire in order to optimize his/her management of fatigue ("educational diagnosis"). an education program, based on a contract of goals will be proposed after this diagnosis phase. the expected results are, in the short-term, a significant reduction in the mean level of fatigue in patients receiving chemotherapy who benefited from individual educational management. in the longer term, the aim is to evaluate the impact of this program on patient quality of life and use of healthcare structures in comparison with conventional management.


Eligibility criteria:
inclusion criteria: * - age\> 18 years. * patient with histologically confirmed malignancy, during initial treatment with chemotherapy, followed or not by surgery, or the first week of radiotherapy. patients with hematologic malignancy (including non-hodgkin's lymphoma or hodgkin's disease) may be included in the study, except for patients with leukemia. * having a fatigue up during the week preceding the inclusion level measured by the average patient with 2 or more on a visual analogue scale (vas) graded from 0 to 10 (0 expressing no fatigue and 10 the maximum fatigue imaginable ). * volunteered to participate in peps "coping with fatigue." * usually followed as outpatients. * condition preserved (ecog ps 2). * available for all meetings of the educational program (5 sessions of 2 hours over a period of 5 weeks). * able to read, write and understand french. * resident (s) in a 50 km radius around the center investigator. * can be contacted by phone. * compulsory membership of a social security system. * obtaining informed consent in writing, signed and dated. exclusion criteria: * - patient (e) with the inclusion anemia with a hemoglobin level below 10 g/100 ml. * patient (e) having a documented history of cognitive or psychiatric disorders. * patient (e) can not be followed for family, social, geographical or psychological. * patient (e) deprived of their liberty by court or administrative

Keywords: cancer fatigue program education
influenza vaccine and pneumococcal vaccine

Conditions: Influenza, Human; Pneumococcal Infections

Summary: previous studies have demonstrated the immunogenicity and safety of the co-administration of the trivalent inactivated influenza vaccine (iiv3) with the polysaccharide pneumococcal vaccine (ppv) or pneumococcal conjugate vaccine (pcv). however, there is no direct comparison study that evaluates the immunogenicity and safety of iiv3 given concomitantly with pcv13 or ppv23 in the elderly. this study is intended to compare the immunogenicity and safety of concomitant administration in the elderly subjects.

during the influenza vaccination period, 224 healthy elderly volunteers randomly received iiv3 given concomitantly with either pcv13 (pcv13+iiv3) or ppv23 (ppv23+iiv3) in a 1:1 ratio. serum hemagglutination-inhibiting (hi) antibodies for iiv3 were measured at the time of vaccination and 1 month after vaccination. adverse events were recorded prospectively in a clinical diary during a 7-day period.

Eligibility criteria:
inclusion criteria: * adults aged ≥65 years who signed the informed consent exclusion criteria: * previous pneumococcal vaccine recipients * egg allergy * history of serious adverse event after vaccination * any acute disease or infection * history of neurological symptoms or signs * impairment of immune function or immunosuppressant use * bleeding diathesis * fever (defined as axillary temperature ³38.0°c) within 3 days * history of streptococcal pneumoniae infection within the previous 5 years

Keywords: influenza vaccine pneumococcal vaccine simultaneous vaccination
transmagnetic stimulation pilot in primary progressive aphasia

Conditions: Primary Progressive Aphasia

Summary: frontotemporal degeneration (ftd) is a non-alzheimer's dementia that is the 2nd most common cause of dementia in the united states. ftd may present with focal language symptoms that are clinically described as primary progressive aphasia (ppa). there are two types of ppa associated with ftd-semantic variant primary progressive aphasia (sv-ppa) and nonfluent/agrammatic variant primary progressive aphasia (nfv-ppa). both diseases are progressive neurodegenerative disease processes that compromise dominant hemisphere large scale brain network function, ultimately resulting in mutism. there are currently no fda-approved treatments for ppa and management is mostly supportive. in combination with resting state functional mri (rs-fmri), transcranial magnetic stimulation (tms) with intermittent theta burst stimulation (itbs) offers a non-invasive alternative to pharmacotherapy in persons with ppa. in our prior studies of alzheimer's disease (ad) and lewy body dementia (lbd) subjects, investigators have determined that the anterior temporal pole (area tgd and tgv) is an area that is commonly dysfunctional in dementia. the investigators have already embarked upon an fmri guided study of itbs in early stage alzheimer's disease where subjects received a series of 5 treatments to distinct brain regions inclusive of area tgd. the investigators propose a case study of 3 ppa studies where rs-fmri is applied to the large-scale language networks.


Eligibility criteria:
inclusion criteria: 1. established diagnosis of nfv-ppa and sv-ppa based on criteria (gorno-tempini et al., 2011) 2. prior brain imaging performed 3. mini mental status exam (mmse)\>10 4. subjects are between 40-90 years of age exclusion criteria: 1. non-ftd dementia including, but not limited to alzheimer's, disease, lewy body dementia, frontotemporal dementia, vascular dementia, jakob-creutzfeldt disease, etc. 2. inability to tolerate rs-fmri 3. contraindication of rs-fmri due to implants or metal 4. seizure disorder

Keywords: transmagnetic stimulation functional mri guided theta burst stimulation
neoadjuvant therapy of icotinib in epidermal growth factor receptor mutated nsclc patients

Conditions: Non-small-cell Lung Cancer

Summary: the purpose of this study is to evaluate the overall response rate and disease free survival for iiian2 non-small-cell lung cancer patients with egfr 19 or 21 exon mutation.

neoadjuvant therapy has been used for years to treat patients with non-small-cell lung cancer whose primary tumors are too large to allow for surgery. reduction in size of the primary tumor with neoadjuvant therapy has made it possible for those patients. moreover, the goals have expanded to include: determination of the sensitivity of the tumor so that subsequent therapy can be modified accordingly; to prolong disease free survival; to prolong survival.

Eligibility criteria:
inclusion criteria: * 1.the patients signed the written informed consent. 2.the patients present with operable iiian2 non-small-cell lung cancers with 19 or 21 exon mutation. 3.the patients have no history of anti-cancer therapies including chemotherapy, radiation therapy, and surgical therapy. 4.the patients' eastern cooperative oncology group scores are ≤ 0-1. 5.the age of patient is ≥ 18 years old with a life expectancy longer than 3 months. exclusion criteria: * 1. patients with unresected tumor. 2. wild egfr type. 3. allergic to the study drug. 4. patients have severe non-cancerous diseases. 5. patients are undergoing current administration of anti-cancer therapies, or are attending some other clinical trials.
validity and reproducibility of osnd (objective score of nutrition on dialysis) as a nutritional marker in end-stage renal disease

Conditions: Malnutrition-Inflammation Syndrome; Hemodialysis Nutritional Risk Stratification

Summary: this prospective observational study is planned to validate osnd against the prospective morbidity and mortality in chronic hemodialysis patients and to examine the hypothesis that osnd risk stratification of chronic hd patients is useful in predicting outcomes and better than its component alone or in diverse combinations. the investigators specific aim is to validate osnd in chronic hd patients by comparing it with conventional measures of nutritional state, including blood tests, anthropometry, mis, gnri, bioelectric impedance analysis and several measures of clinical outcome including prospective mortality and hospitalization.


Eligibility criteria:
inclusion criteria: 1. male or female, age \> 18 years, in chronic hemodialysis treatment at least 3 months 2. stable and adequate hemodialysis treatment three months prior to participation in study as defined by kt/v \> 1.2 and/or hemodialysis performed 4 hours 3 times weekly 3. patients with normal hydration status (edema-free), with no neuroid-muscular diseases 4. informed consent obtained before any trial-related activities exclusion criteria: 1. patients with edema, pleural effusion or ascites at their initial assessment 2. patients with active malignant disease or liver cirrhosis 3. patients with neuroid-muscular diseases 4. patients on chronic treatment with steroids on doses \> 10 mg/day prednisone (or equivalent) 5. patients treated with immunosuppressive agents 6. patients suffering from * acute vasculitis * severe systemic infections * heart failure (nyha class iii-iv)

Keywords: hemodialysis inflammation malnutrition phase angle
safety of oral immunotherapy for cow's milk allergy in school-aged children

Conditions: Milk Allergy; Anaphylaxis

Summary: the purpose of this study is to study the number of participants with adverse events as a measure of safety and tolerability.

eligibility criteria: age 6 - 16 yrs * ige-mediated milk allergy * and milk provocation within 3 months prior to or an documented accidental milk contact with clear immediate symptoms outcome measures: * number of patients with successful desensitization (195 - 200 ml milk per day) * number of patients with adverse events

Eligibility criteria:
inclusion criteria: * ige-mediated milk allergy * an immediately positive challenge test result to milk prior to inclusion exclusion criteria: * not willing to participate

Keywords: milk allergy desensitization anaphylaxis school-age
effects of external electric stimulating in individuals with urinary incontinence after prostatectomy

Conditions: Urinary Incontinence

Summary: the aim of this study is to investigate effects of external electric stimulating in individuals with urinary incontinence after prostatectomy.

urinary incontinence (ui) is common in men after prostotectomy, and patients' quality of life is adversely affected. in addition, electric stimulation (es) can be played an important role in the management of ui . however, there are limitations in clearly demonstrating the effects of es on men with ui after prostatectomy.

Eligibility criteria:
inclusion criteria: * being a male individual with stress or stress-dominant mixed ui symptoms after undergoing prostatectomy surgery for prostate cancer in the urology clinic * being over 40 years old * being 24 and over with mini mental test results in individuals over 65 years of age. * not having residual cancerous tissue * volunteering to participate in the study exclusion criteria: * having serious cardiovascular disease (unstable angina and arrhythmia patients, heart failure patients, etc.) * having sensory loss * having an ongoing urinary infection * having only urgency urinary incontinence * using a pacemaker * receiving active cancer treatment (radiotherapy, chemotherapy) * lack of evaluation parameters * not continuing the treatment regularly
first in human study of the doraya catheter for the treatment of ahf patients

Conditions: Acute Heart Failure

Summary: safety and performance evaluation of the doraya catheter in patients admitted with ahf.

the purpose of this clinical investigation is to evaluate the safety and performance of the doraya catheter in patients admitted with ahf, presenting persistent volume over load and poor response to diuretic treatment.

Eligibility criteria:
inclusion criteria: * ahf subjects with poor diuretic response exclusion criteria: * ahf subjects with sufficient diuretic response
comparative therapeutic efficacy and safety of different antiviral and anti inflammatory drugs in covid-19 patients.

Conditions: Covid19; Pneumonia

Summary: comparison outcomes of a large cohort of moderate and severe covid-19 patients received different antiviral and anti inflammatory drugs.

aim of the study 1. to assess the difference in patients' clinical status improvement between patients. 2. to detect time to improvement in oxygenation among both groups. 3. to detect duration of hospitalization and mortality rate in both groups. 4. to detect incidence and duration of mechanical ventilation in both treatment arms. 5. to monitor of adverse events of both drugs

Eligibility criteria:
inclusion criteria: * hospitalized adult patients with pneumonia evidenced by chest ct scan. * laboratory (rt-pcr) confirmed infection with 2019-ncov or strongly suspected to be infected with sars-cov2 with confirmation studies pending. * and at least one of the following: 1. respiratory frequency ≥30/min. 2. blood oxygen saturation ≤93% on room air (ra). 3. partial pressure of arterial oxygen to fraction of inspired oxygen ratio (pao2/fio2) \<300. 4. worsening of lung involvement, defined as an increase in number and/or extension of pulmonary areas of consolidation, need for increased fio2 to maintain stable o2 saturation, or worsening o2 saturation of \>3% with stable fio2. exclusion criteria: * baseline elevation of alanine aminotransferase (alt) or aspartate aminotransferase (ast) levels \> 3-fold the upper limit of the normal range. * pregnancy.

Keywords: covid19
correlation study of serum her 2 against her 2-adc drug efficacy in her 2 low-expressing breast cancer

Conditions: HER 2 Low-expressing Breast Cancer

Summary: breast cancer is one of the most common malignancies in women worldwide, with her2-positive breast cancer accounting for about 15-20% of all breast cancer cases. her2 (human epidermal growth factor receptor 2) is a tyrosine kinase receptor that, when overexpressed, promotes the growth and spread of tumor cells. the advent of anti-her2 therapy, particularly antibody-coupled drugs (adcs), has resulted in significant survival benefits for her2-positive breast cancer subjects. at present, the value of serum her2 in the monitoring of anti-her2-adc drug therapy is insufficient. the purpose of this study was to investigate changes in serum her2 expression levels in breast cancer subjects treated with anti-her2-adc drugs and the relationship between these changes and treatment effect. the therapeutic effect of her2 was evaluated by continuous detection of her2 serum, which provided a theoretical basis for the selection of clinical drug treatment.

adc drugs are a new type of targeted therapy. adc drugs are composed of monoclonal antibodies, linkers and drug carriers, which bind to the target antigen on the surface of tumor cells through antibodies, endocytosis/internalization to form early endosomes in cells, and then mature into late endosomes and fuse with lysosomes. adc drugs break apart in the lysosome and release the drug carrier, eventually leading to apoptosis or death while minimizing damage to normal cells. however, not all subjects with her2-positive breast cancer respond well to adc drugs, and resistance may develop during treatment. therefore, effective biomarkers are needed to monitor treatment effects and guide individualized treatment. serum her2 refers to the her2 protein fragment present in the subject's serum. serum her2 levels may be more readily available than her2 expression in tumor tissue and can be sampled multiple times during treatment, allowing real-time monitoring of disease progression and drug efficacy. if monitoring of serum her2 levels accurately reflects tumor sensitivity to adc drugs, it could be a valuable therapeutic monitoring tool. in view of the excellent efficacy of adc drugs in her2-positive and low-expression breast cancer patients, this study intends to judge the therapeutic efficacy of breast cancer patients treated by anti-her2-adc drugs (such as t-dxd) through continuous detection of their serum her2, providing a theoretical basis for the selection of clinical drug therapy.

Eligibility criteria:
inclusion criteria: * 1. subjects with pathologically confirmed breast cancer; 2. the therapeutic drugs are anti-her2-adc drugs; 3. no history of other tumors; 4. age \> 18 years old; 5. have relatively complete clinical case characteristics data. exclusion criteria: * 1. male breast cancer subjects; 2. suffering from other malignant neoplasms; 3. subjects with incomplete clinical case characteristics.
a study of induction dosing with peginterferon alfa-2a and ribavirin in participants with chronic hepatitis c (chc) genotype 1 infection

Conditions: Hepatitis C, Chronic

Summary: this study will evaluate the addition of a higher-dose induction treatment period with peginterferon (peg-ifn) alfa-2a (pegasys) and ribavirin prior to standard-dose treatment with peg-ifn alfa-2a and ribavirin, compared to standard-dose treatment, in treatment-naive participants with chc, genotype 1 infection.


Eligibility criteria:
inclusion criteria: * diagnosis of chronic chc, genotype 1 * chronic liver disease consistent with chc on a biopsy sample obtained within the previous 36 months as judged by a local pathologist (all countries except australia) * infection with hepatitis c virus (australian sites only had to meet section 100 criteria for treatment with peg-ifn alfa-2a plus ribavirin) * compensated liver disease * naive to interferon-based therapy for chc infection exclusion criteria: * systemic antiviral, antineoplastic, or immunomodulatory treatment within 6 months of study drug * coinfection with active hepatitis a or b virus, or with human immunodeficiency virus (hiv) * chronic liver disease other than chc infection